MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/29767342251389751

Медицинская библиотека · Substance use & addiction journal · 2025

Self-Reported and Biologic Assessments of Prenatal Cannabis Use: Ancillary Analysis of a Prospective Observational Cohort.

Devlin Paulina M, Allshouse Amanda A, McMillin Gwen, Chung Judith H, Grobman William A, Haas David M, Pippen Jessica L, Parry Samuel, Reddy Uma M, Saade George R, Simhan Hyagriv N, Silver Robert M, Metz Torri D

СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

We evaluated agreement between self-reports of prenatal cannabis use and biologic assays, and identified factors associated with discordance.

METHODS

Ancillary analysis of the "Nulliparous Pregnancy Outcomes Study: Monitoring Mothers to Be" (nuMoM2b) study, a United States multicenter prospective cohort of pregnant individuals from October 2010 to September 2013. Past 30-day self-reported prenatal cannabis use was assessed at nuMoM2b study visit 2 (16 weeks and 0 days-21 weeks and 6 days), visit 3 (22 weeks and 0 days-29 weeks and 6 days), and at delivery. Biologic detection of cannabis metabolite (11-nor-9-carboxy-delta-9-tetrahydrocannabinol) was performed with urine samples from visit 2 and visit 3 and the umbilical cord at delivery. The agreement between self-report and biologic assay was evaluated with a Kappa statistic. Factors associated with discordance were evaluated with multivariable logistic regression.

FINDINGS: Nine thousand one hundred sixteen participants were included, and 434 (4.76%) used cannabis by either self-report or biologic assay. Among participants who used cannabis, 74.5% of prenatal cannabis use at visit 2 and 79.6% of prenatal cannabis use at visit 3 was detected via urine assay and not self-report. Eighty-nine point seven percent of prenatal cannabis at delivery use was detected via cord assay and not self-report. The agreement between self-report and biospecimen assay was fair at visit 2 (Kappa 0.30, 95% confidence interval [CI] 0.24-0.36), fair at visit 3 (Kappa 0.23, 95% CI 0.17-0.29), and slight at delivery (Kappa 0.11, 95% CI 0.01-0.21). Age <30 years, being unmarried, government insurance, and moderate or high perceived stress were associated with discordance between self-reported use and biologic assay.

CONCLUSIONS

Nearly threefold more prenatal cannabis use was detected by biologic assay compared with self-report. The agreement was fair between self-report and urine assay during pregnancy and slight between self-report and umbilical cord assay at delivery. Several sociodemographic factors were associated with discordance between self-reported use and biologic assay results.

Для цитирования: Devlin Paulina M, Allshouse Amanda A, McMillin Gwen, Chung Judith H, Grobman William A, Haas David M, Pippen Jessica L, Parry Samuel, Reddy Uma M, Saade George R, Simhan Hyagriv N, Silver Robert M, Metz Torri D. Self-Reported and Biologic Assessments of Prenatal Cannabis Use: Ancillary Analysis of a Prospective Observational Cohort.. Substance use & addiction journal. 2025. DOI: 10.1177/29767342251389751.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.